1. Canada Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Excelsior Biopharma Inc.

Excelsior Biopharma Inc.

6496.TWO
Excelsior Biopharma Inc.TW flagTaipei Exchange
25.35
TWD
+0.45
- -
1.18BMarket Cap
Excelsior Biopharma Inc.
6496.TWO
(Taipei Exchange)

Recent

price

25.35

P/E

ratio

- -

div

yld

- -

ROIC.AI

2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
24.81
26.98
29.13
32.95
36.76
36.2
33
30.94
28.78
14.39
16.8
18.69
- -
14.91
Revenue per Share
- -
4.08
3.62
3.37
3.87
5.99
4.75
1.52
0.76
-0.34
-0.72
-1.98
-2.14
- -
-2.76
Basic EPS, GAAP
- -
2.74
2.58
0.04
3.82
7.13
2.52
-4.07
10.91
1.14
-0.05
-3.71
-7.74
- -
-2.2
Free Cash Flow per Basic Share
- -
1.3
2.4
2.5
2.5
4
4
4
1
1
- -
- -
- -
- -
- -
Dividend per Share
- -
17.11
16.79
16.56
16.32
18.89
20.04
18.06
17.95
16.64
16.14
14.48
12.26
- -
8.21
Book Value per Share
- -
18.09
17.68
19.34
26.77
28.71
29.42
26.89
27.49
26.45
25.87
24.05
21.5
- -
17.36
Tangible Book Value per Share
- -
38
42
42
47
47
47
47
47
47
47
46
46
- -
46
Basic Weighted Avg Shares
- -
954
1,147
1,238
1,535
1,716
1,689
1,540
1,444
1,338
672
772
862
898
691
Sales/Revenue/Turnover
- -
18.53
17.08
14.14
14.04
18.99
16.69
5.57
2.83
-0.32
-4.91
-10.39
-9.13
-19.39
-17.73
Operating Margin (%)
- -
15
22
22
24
25
25
29
27
29
26
46
71
72
54
Depreciation Expense
- -
157
154
143
180
280
222
71
35
-16
-34
-91
-99
-183
-128
Net Income, GAAP
- -
19.06
21
19.11
17.46
16.94
22.42
22.66
22.07
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
16.45
13.42
11.58
11.76
16.3
13.13
4.61
2.45
-1.17
-5.03
-11.8
-11.45
-20.39
-18.53
Profit Margin (%)
457
505
574
645
1,070
1,156
1,194
1,039
1,374
1,282
984
818
548
355
355
Working Capital
- -
- -
- -
- -
- -
- -
- -
75
361
351
43
300
356
302
302
LT Debt
607
695
751
822
1,247
1,340
1,373
1,255
1,283
1,230
1,207
1,104
991
804
804
Total Equity
- -
20.58
19.59
16.29
15.9
19.49
15.27
4.76
2.09
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
28.92
21.09
18.56
22.66
31.67
23.48
7.59
3.39
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
28.05
22.45
20.22
24.65
34.06
24.42
7.99
4.2
-1.94
-4.42
-12.84
-16.05
-38.73
-27.08
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
ST Debt
75
- -
232
LT Borrowings
110
- -
110
LT Finance Leases
216
- -
192
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
47
47
47
Market Capitalization
1,111
1,365
1,355

Working Capital

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
Total Current Assets
638
- -
726
Cash, Cash Equivalents & STI
152
- -
185
Accounts Receivable, Net
164
- -
231
Inventories
295
- -
285
Total Current Liabilities
188
- -
372
Payables & Accruals
- -
- -
- -
ST Debt
75
- -
232
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
1.17%
-8.72%
-18.88%
Free Cash Flow
1,750.53%
1,436.68%
-50.79%
Net Income, GAAP
17.69%
47%
85.57%
Sales/Revenue/Turnover
-0.72%
-5.26%
4.22%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
188
188
187
209
772
2024
190
213
218
241
862
2025
210
202
- -
279
898

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
-0.52
-0.79
-0.81
- -
-1.98
2024
-0.73
-0.46
-0.48
- -
-2.14
2025
-0.89
-1.03
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Excelsior Biopharma Inc. (6496.TWO)
Khiron Life Sciences Corp. (KHRN.V)
MERCK Kommanditgesellschaft auf Aktien (MER.SW)
Orient Pharma Co., Ltd. (4166.TWO)
Elixinol Wellness Limited (ELLXF)
Glass House Brands Inc. (GLASF)
Business
Excelsior Biopharma Inc. develops, manufactures, and sells pharmaceutical products in Taiwan, China, and internationally. The company offers prescription drugs, over-the-counter drugs, medical devices, healthcare food products, medical supplies, and other products for therapeutic areas including pediatrics, gastroenterology, neurology, cardiology, dermatology, medical toxicology, dentistry, obstetrics, oncology, hematology, otorhinolaryngology, and infectious diseases; test kits under the Actim brand to detect influenza virus, fecal occult blood, acute pancreatitis, preterm or full-week delivery, and early water breaking; toothpaste, mouthwash, and gel products under the Oral7 brand; food and medical beauty maintenance products; and imports and exports active pharmaceutical ingredients while engaging in pharmaceutical technology research, transfer, cooperative development, and improvement activities. Incorporated in 1988 and headquartered in Taipei, Taiwan, the company operates primarily in the healthcare sector, targeting hospitals, clinics, and consumers with a focus on rare and niche specialty diseases across Southeast Asia through subsidiaries such as Excelsior Biotech (Malaysia) SDN. BHD., established in February 2020. Formerly known as Excelsior Enterprise Co., Ltd., it changed its name to Excelsior Biopharma Inc. in June 2003; recent activities include advancing a preclinical pipeline featuring Agalsidase alfa for Fabry Disease, EX-054 for lysosomal storage diseases, and TGF-β-targeted candidates like EX042-002 series for fibrosis, Alzheimer's disease, and neoplasms, alongside ongoing ESG initiatives such as establishing the Excelsior Fellowship Activity Center in 2025 for rare disease patient support and participation in pulmonary hypertension education events.